Graig Suvannavejh
Stock Analyst at Mizuho
(4.63)
# 244
Out of 5,182 analysts
178
Total ratings
56.72%
Success rate
25.05%
Average return
Main Sectors:
Stocks Rated by Graig Suvannavejh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $20 → $41 | $40.89 | +0.27% | 13 | Apr 2, 2026 | |
| IMMX Immix Biopharma | Maintains: Outperform | $14 → $15 | $10.18 | +47.35% | 2 | Mar 30, 2026 | |
| INSM Insmed | Maintains: Outperform | $204 → $206 | $144.48 | +42.58% | 14 | Mar 25, 2026 | |
| PVLA Palvella Therapeutics | Maintains: Outperform | $205 → $250 | $130.64 | +91.37% | 2 | Feb 25, 2026 | |
| LONA LeonaBio | Upgrades: Outperform | $10 | $9.16 | +9.17% | 1 | Feb 19, 2026 | |
| ERAS Erasca | Maintains: Outperform | $4 → $5 | $21.65 | -76.91% | 1 | Dec 9, 2025 | |
| TERN Terns Pharmaceuticals | Maintains: Outperform | $33 → $54 | $52.84 | +2.20% | 9 | Dec 9, 2025 | |
| BLTE Belite Bio | Upgrades: Outperform | $105 → $194 | $167.42 | +15.88% | 2 | Dec 2, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $39 → $46 | $31.97 | +43.88% | 21 | Dec 1, 2025 | |
| TARS Tarsus Pharmaceuticals | Initiates: Outperform | $100 | $63.48 | +57.53% | 1 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $23 | $11.26 | +104.26% | 4 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $54 → $56 | $68.40 | -18.13% | 7 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $44 → $46 | $31.67 | +45.25% | 3 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $200 → $202 | $186.42 | +8.36% | 22 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $2 → $4 | $1.15 | +247.83% | 9 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $0.18 | +16,897.17% | 1 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2.5 → $3.5 | $2.45 | +42.86% | 5 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $5 | $2.31 | +116.45% | 2 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $10 | $5.89 | +69.78% | 2 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $11 | $17.85 | -38.38% | 3 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $26 | $14.24 | +82.58% | 5 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $8 | $17.52 | -54.34% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $33 | $29.98 | +10.07% | 8 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7 → $7.6 | $1.60 | +375.00% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $10.48 | +606.11% | 1 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $1 | $2.54 | -60.63% | 5 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $35 | $85.18 | -58.91% | 5 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $8 | $45.19 | -82.30% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $71 → $57 | $66.25 | -13.96% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $5 | $38.31 | -86.95% | 4 | Apr 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $5.25 | +547.62% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $13.37 | +109.42% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $31 | $32.17 | -3.64% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $380 | $15.32 | +2,380.42% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $4.75 | $1.43 | +232.17% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $36 | $23.75 | +51.58% | 2 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $29.13 | - | 1 | Oct 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $37 | $4.31 | +758.47% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $128 | $202.40 | -36.76% | 1 | Sep 14, 2020 |
Apellis Pharmaceuticals
Apr 2, 2026
Maintains: Neutral
Price Target: $20 → $41
Current: $40.89
Upside: +0.27%
Immix Biopharma
Mar 30, 2026
Maintains: Outperform
Price Target: $14 → $15
Current: $10.18
Upside: +47.35%
Insmed
Mar 25, 2026
Maintains: Outperform
Price Target: $204 → $206
Current: $144.48
Upside: +42.58%
Palvella Therapeutics
Feb 25, 2026
Maintains: Outperform
Price Target: $205 → $250
Current: $130.64
Upside: +91.37%
LeonaBio
Feb 19, 2026
Upgrades: Outperform
Price Target: $10
Current: $9.16
Upside: +9.17%
Erasca
Dec 9, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $21.65
Upside: -76.91%
Terns Pharmaceuticals
Dec 9, 2025
Maintains: Outperform
Price Target: $33 → $54
Current: $52.84
Upside: +2.20%
Belite Bio
Dec 2, 2025
Upgrades: Outperform
Price Target: $105 → $194
Current: $167.42
Upside: +15.88%
Harmony Biosciences Holdings
Dec 1, 2025
Maintains: Outperform
Price Target: $39 → $46
Current: $31.97
Upside: +43.88%
Tarsus Pharmaceuticals
Nov 20, 2025
Initiates: Outperform
Price Target: $100
Current: $63.48
Upside: +57.53%
Nov 19, 2025
Maintains: Outperform
Price Target: $19 → $23
Current: $11.26
Upside: +104.26%
Nov 18, 2025
Maintains: Neutral
Price Target: $54 → $56
Current: $68.40
Upside: -18.13%
Nov 11, 2025
Maintains: Outperform
Price Target: $44 → $46
Current: $31.67
Upside: +45.25%
Nov 6, 2025
Maintains: Outperform
Price Target: $200 → $202
Current: $186.42
Upside: +8.36%
Sep 12, 2025
Maintains: Neutral
Price Target: $2 → $4
Current: $1.15
Upside: +247.83%
Sep 8, 2025
Initiates: Outperform
Price Target: $30
Current: $0.18
Upside: +16,897.17%
Jul 28, 2025
Upgrades: Outperform
Price Target: $2.5 → $3.5
Current: $2.45
Upside: +42.86%
Jul 16, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $2.31
Upside: +116.45%
Jun 18, 2025
Maintains: Outperform
Price Target: $8 → $10
Current: $5.89
Upside: +69.78%
May 20, 2025
Maintains: Outperform
Price Target: $12 → $11
Current: $17.85
Upside: -38.38%
May 16, 2025
Maintains: Outperform
Price Target: $30 → $26
Current: $14.24
Upside: +82.58%
May 14, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $17.52
Upside: -54.34%
Apr 7, 2025
Maintains: Neutral
Price Target: $38 → $33
Current: $29.98
Upside: +10.07%
Nov 18, 2024
Upgrades: Buy
Price Target: $7 → $7.6
Current: $1.60
Upside: +375.00%
Sep 20, 2024
Reiterates: Outperform
Price Target: $74
Current: $10.48
Upside: +606.11%
Jun 5, 2023
Downgrades: Neutral
Price Target: $17 → $1
Current: $2.54
Upside: -60.63%
Nov 10, 2022
Maintains: Buy
Price Target: $31 → $35
Current: $85.18
Upside: -58.91%
Nov 10, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $45.19
Upside: -82.30%
May 24, 2022
Maintains: Buy
Price Target: $71 → $57
Current: $66.25
Upside: -13.96%
Apr 19, 2022
Maintains: Sell
Price Target: $8 → $5
Current: $38.31
Upside: -86.95%
Jun 1, 2021
Initiates: Buy
Price Target: $34
Current: $5.25
Upside: +547.62%
Apr 20, 2021
Initiates: Neutral
Price Target: $28
Current: $13.37
Upside: +109.42%
Apr 19, 2021
Initiates: Neutral
Price Target: $31
Current: $32.17
Upside: -3.64%
Mar 2, 2021
Initiates: Sell
Price Target: $380
Current: $15.32
Upside: +2,380.42%
Nov 24, 2020
Initiates: Neutral
Price Target: $4.75
Current: $1.43
Upside: +232.17%
Nov 9, 2020
Upgrades: Buy
Price Target: $36
Current: $23.75
Upside: +51.58%
Oct 21, 2020
Downgrades: Sell
Price Target: n/a
Current: $29.13
Upside: -
Oct 20, 2020
Initiates: Neutral
Price Target: $37
Current: $4.31
Upside: +758.47%
Sep 14, 2020
Downgrades: Sell
Price Target: $128
Current: $202.40
Upside: -36.76%